Department of Chemistry and Pharmaceutical Technologies, University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.
Curr Drug Deliv. 2010 Apr;7(2):109-17. doi: 10.2174/156720110791011792.
5-Fluorouracil (5-FU) is currently used for treatment of oral squamous cell carcinoma (OSCC). 5-FU is given by i.v. although the systemic administration is associated with severe toxic effects and no topical formulations of 5-FU for buccal drug delivery have been reported. In this study we would report the development of buccal tablets suitable for direct application of low-doses of 5-FU on cancer lesions. The topical administration could be effective on tumor area while systemic undesired side effects are avoided. Preliminarily, the limited tendency of 5-FU to cross the buccal tissue was established using reconstituted human oral epithelium (RHOE, in vitro) and porcine buccal mucosa (ex vivo) as mucosal models. The values of steady-state flux and permeability coefficient suggested the scarce aptitude of 5-FU to reach the systemic circulation. Matrix buccal tablets, were designed for 5-FU local delivery, developed and prepared. Release tests showed a highly reproducible Higuchian drug discharge. After tablet administration on buccal tissue specimens, the occurrence of histo-morphological effects of 5-FU was highlighted. Apoptotic events were registered in all samples treated while only negligible amounts of 5-FU permeated the buccal membrane and reached the simulated plasma. The results suggest that loaded matrix tablets containing 5% of 5-FU could be a useful means in topical treatment of OSCC.
5-氟尿嘧啶(5-FU)目前用于治疗口腔鳞状细胞癌(OSCC)。5-FU 是通过静脉注射给药的,尽管全身给药与严重的毒性作用相关,但尚未报道用于口腔给药的 5-FU 局部制剂。在这项研究中,我们将报告开发适合直接应用于癌症病变的低剂量 5-FU 的颊片剂。局部给药可以在避免全身不良副作用的情况下对肿瘤区域产生效果。初步研究使用重建的人口腔上皮(RHOE,体外)和猪口腔黏膜(离体)作为黏膜模型,证实了 5-FU 有限的跨颊组织能力。稳态通量和渗透系数值表明 5-FU 很少有进入体循环的能力。设计了用于局部递送 5-FU 的基质颊片剂,并进行了开发和制备。释放试验显示出高度重现性的 Higuchi 药物释放。在颊组织标本上给药后,突出显示了 5-FU 的组织形态学作用的发生。所有接受治疗的样本中均记录到了凋亡事件,而只有少量的 5-FU 穿透颊膜并到达模拟血浆。结果表明,含有 5%5-FU 的负载基质片剂可能是治疗口腔鳞状细胞癌的一种有用手段。